U.S. Withdrawal from WHO: Implications and Background
In a recent move, President Trump signed an executive order announcing the United States' withdrawal from the World Health Organization (WHO). This marks a repeat action, as Trump had previously initiated the exit process during his first term.
Historical Context
On July 6, 2020, the Trump administration formally notified UN Secretary-General Antonio Guterres of its intent to leave the WHO, with an effective exit date set for July 6, 2021. This decision faced significant backlash both internationally and domestically. However, upon taking office in 2021, President Biden reversed the withdrawal, reaffirming the U.S. commitment to the organization.
Reasons for Withdrawal
The recent executive order cites two primary reasons for the exit:
Ineffectiveness in Handling COVID-19: The White House criticized WHO for its inadequate response to the COVID-19 pandemic, asserting that the organization failed to provide timely and appropriate measures.
Excessive Membership Fees: The administration expressed concerns over what it deemed unfairly high membership fees demanded by WHO, which were perceived as disproportionate compared to other countries' contributions.
Furthermore, Trump announced that the U.S. would suspend all government funding or resources to WHO moving forward.
Potential Impacts
According to WHO's official website, the organization has two primary funding sources: assessed contributions (membership fees) and voluntary donations. The assessed contributions account for less than 25% of WHO's budget, with the remainder obtained through voluntary donations from member states and other partners.
In addition to contributing approximately $110 million annually in assessed fees, the U.S. has been a leading voluntary donor, contributing $1.1 billion between 2022 and 2023. Overall, the U.S. has provided around 20% of WHO's total budget.
Experts, such as global health specialist Ilona Kickbusch, warn that the consequences of the U.S. withdrawal could be significant. The departure will sever connections between WHO and key U.S. health institutions, including the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). Virologist Marion Koopmans from the Erasmus Medical Center in the Netherlands remarked, “The U.S. exit will impede the CDC’s access to critical intelligence vital for global safety.”
The U.S. withdrawal from WHO not only raises concerns about future global health cooperation but also highlights the ongoing tensions surrounding international health governance. As the world continues to navigate public health crises, the absence of U.S. leadership in WHO could have far-reaching effects on global health initiatives.
Looking for chemical products? Let suppliers reach out to you!
2026-07-11
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
Sun Pharma’s Secret Sauce: Solve the Specific, Win the Market
-
The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
-
Sun Pharma’s Winning Formula: Precision Over Expansion
-
Merck to Lay Off 150 Workers at US Gardasil Plant Amid Sales Weakness
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
AstraZeneca India Eyes ₹3,400 Crore Bengaluru Sale
-
Iran Conflict Leaves a Long Shadow on Drug Supply
-
Sun Pharma’s Organon Bid Would Redraw Indian Pharma M&A
Recommend Reading
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
FDA Fast-Tracks U.S. Drug Manufacturing
-
India’s Pharma Cost Problem Gets Worse
-
India Targets Fake Drug Packaging
-
Kering and L'Oréal Form $4 Billion Strategic Alliance in Luxury Beauty and Wellness
-
Salinity Solution: Preparation and Uses
-
Premium Global Chemical Sourcing Requests (13-17 Oct 2025)
-
Wacker Opens Biotechnology Center in Munich
-
Semcorp's Hungarian Factory Ordered to Shut Down Over Pollution